University of Catanzaro Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2018
NCT03791775
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Azienda Ospedaliera Universitaria Mater Domini, Catanzaro | Azienda Ospedaliera Universitaria Mater Domini - Università Magna Graecia di Catanzaro | Department of Medical and Surgical Sciences, University of Catanzaro, Catanzaro 88100, Italy

Active Ingredients

Drugs in Phase 2 Trials (2)

onabotulinumtoxinA (Botox) (1 trial)

polidocanol (asclera) (1 trial)

Drugs in Phase 1 Trials (1)

lna-i-mir-221 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemorrhoids (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3